MedTrace Logo

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 562

Last updated 2013-04-17

No results posted yet for this study

Summary

This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.

Conditions

  • Hypoactive Sexual Desire Disorder

Interventions

DRUG

Testosterone Transdermal System

testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks

DRUG

Placebo

placebo patch,changed every 3-4 days for 24 weeks during double blind phase

Sponsors & Collaborators

  • Warner Chilcott

    lead INDUSTRY

Principal Investigators

  • Johna Lucus, MD · Procter and Gamble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2003-12-31
Completion
2006-07-31

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331123 on ClinicalTrials.gov